Key result
Perindopril reduces and prevents cardiovascular disease in a wide range of patients with vascular diseases, beyond its blood pressure-lowering effects.
Perindopril provides cardiovascular protection beyond blood pressure lowering, improving outcomes in patients with various vascular diseases.
May support perindopril in vascular disease beyond BP effects; leaves open class-specific benefits and needs prospective trials.
Perindopril, a prodrug ester of perindoprilat, is an angiotensin-converting enzyme inhibitor that lowers angiotensin II and potentiates bradykinin. This agent has proven efficacy in a wide range of cardiovascular diseases. Its efficacy, safety and tolerability are well established in the treatment of hypertension. Beyond pharmacodynamic effects shown in lowering blood pressure, perindopril was also involved in the improvement of endothelial function and the normalization of vascular and cardiac structure and function. Large morbidity-mortality trials, such as the European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease (EUROPA), Perindopril Protection Against Recurrent Stroke Study (PROGRESS) and Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), have shown that treatment with perindopril reduces and prevents cardiovascular disease in a large range of patients with vascular diseases (including stable coronary disease), whether or not they are hypertensive.
No takes yet. Share an insight, caveat, or question.
Zaïem et al. (2008) conducted a review in Cardiovascular diseases and hypertension. Perindopril was evaluated. Perindopril reduces and prevents cardiovascular disease in a wide range of patients with vascular diseases, beyond its blood pressure-lowering effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: